Bandyszewska Magdalena, Ambrożek-Latecka Magdalena, Hoser Grażyna, Grzanka Małgorzata, Hornung Franziska, Deinhardt-Emmer Stefanie, Skirecki Tomasz
Department of Translational Immunology and Experimental Intensive Care, Centre of Translational Research, Centre of Postgraduate Medical Education, Warsaw, Poland.
Department of Biochemistry and Molecular Biology, Centre of Translational Research, Centre of Postgraduate Medical Education, Warsaw, Poland.
Antiviral Res. 2024 Apr;224:105857. doi: 10.1016/j.antiviral.2024.105857. Epub 2024 Mar 5.
The emerging SARS-CoV-2 variants are evolving to evade human immunity and differ in their pathogenicity. While evasion of the variants from adaptive immunity is widely investigated, there is a paucity of knowledge about their interactions with innate immunity. Inflammasome assembly is one of the most potent mechanisms of the early innate response to viruses, but when it is inappropriate, it can perpetuate tissue damage. In this study, we focused on the capacity of SARS-CoV-2 Alpha and Delta variants to activate the NLRP3 inflammasome. We compared the macrophage activation, particularly the inflammasome formation, using Alpha- and Delta-spike virus-like particles (VLPs). We found that VLPs of both variants activated the inflammasome even without a priming step. Delta-spike VLPs had a significantly stronger effect on triggering pyroptosis and inflammasome assembly in THP-1 macrophages than did Alfa-spike VLPs. Cells treated with Delta VLPs showed greater cleavage of caspase-1 and IL-1β release. Furthermore, Delta VLPs induced stronger cytokine secretion from macrophages and caused essential impairment of mitochondrial respiration in comparison to Alpha VLPs. Additionally, infection of primary human monocyte-derived macrophages with the SARS-CoV-2 variants confirmed the observations in VLPs. Collectively, we revealed that SARS-CoV-2 Delta had a greater impact on the inflammasome activation, cell death and mitochondrial respiration in macrophages than did the Alpha variant. Importantly, the differential response to the SARS-CoV-2 variants can influence the efficacy of therapies targeting the host's innate immunity.
新出现的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体正在不断进化以逃避人类免疫,并且它们的致病性也有所不同。虽然对这些变体逃避适应性免疫的情况进行了广泛研究,但对于它们与先天免疫的相互作用却知之甚少。炎性小体组装是病毒早期先天反应最有效的机制之一,但如果不适当,它会使组织损伤持续存在。在本研究中,我们重点关注了SARS-CoV-2 Alpha和Delta变体激活NLRP3炎性小体的能力。我们使用Alpha和Delta刺突病毒样颗粒(VLP)比较了巨噬细胞的激活情况,特别是炎性小体的形成。我们发现,即使没有预激活步骤,两种变体的VLP也能激活炎性小体。Delta刺突VLP对THP-1巨噬细胞中焦亡和炎性小体组装的触发作用明显强于Alfa刺突VLP。用Delta VLP处理的细胞显示出半胱天冬酶-1的切割和白细胞介素-1β释放更多。此外,与Alpha VLP相比,Delta VLP诱导巨噬细胞分泌更强的细胞因子,并导致线粒体呼吸的基本损伤。此外,用SARS-CoV-2变体感染原代人单核细胞衍生的巨噬细胞证实了在VLP中的观察结果。总体而言,我们发现SARS-CoV-2 Delta对巨噬细胞中炎性小体激活、细胞死亡和线粒体呼吸的影响比Alpha变体更大。重要的是,对SARS-CoV-2变体的不同反应可能会影响针对宿主先天免疫疗法的疗效。